Respiratory medical device company ALung recently announced the completion of Series C financing, amounting to US$36 million, led by Royal Philips and UPMC, Abiomed, The Accelerator Fund, Allos Ventures, Birchmere Ventures, Blue Tree Ventures and Riverfront Ventures. Funding for this round of financing is expected to be used in key tests for Hemolung's respiratory assist system in the United States with FDA approval. CEO Peter DeComo said that the next clinical trial in the United States will be an important step in obtaining FDA approval and making the device suitable for US patients. ALung had a total of $35.8 million in Series B financing and $14 million in Series A in 2010. ALung is based in Pittsburgh, PA, and was established in 1997. It officially began commercial operations in 2001. The company is developing the Hemolung device, an in vitro carbon dioxide removal system. Hemolung RAS development began in 2005, began human clinical trials in 2010, and obtained CE certification in 2013. ALung CEO Peter DeComo said that since 2013, Hemolung RAS has helped hundreds of patients with acute respiratory failure outside the United States to successfully treat. It acts by removing carbon dioxide and delivering oxygen directly into the patient's blood through a small catheter inserted into the jugular or femoral vein. The Hemolung device is designed to simplify extracorporeal pulmonary respiration support, and the Hemolung Respiratory Assist System provides partial respiratory support using a "respiratory dialysis" technique similar to renal dialysis. What is respiratory dialysis? Respiratory dialysis is a simple, minimally invasive method for the in vitro CO2 removal in patients with acute hypercapnia respiratory failure. Hemolung RAS provides a simple use of extracorporeal circuits, low blood flow and venous-venous catheter breathing dialysis. For acute exacerbations of COPD, respiratory dialysis can prevent intubation, avoid invasive mechanical ventilation, reduce breathing, correct acidosis, and give patients time to recover from acute decompensation. For acute respiratory distress syndrome (ARDS), lung protection ventilation can be activated, allowing gradual escalation of the ventilator settings while correcting acidosis. Unlike other forms of ECCO2R, the implementation of respiratory dialysis is simple. Hemolung RAS uses only a 15.5Fr venous catheter for vascular access, without arterial puncture, and the blood flow through the circuit is only 350-550ml / min. Hemolung RAS's innovative "active mixing" design allows clinically significant CO2 to be continuously removed at low blood flow rates for up to 7 days without the need to replace the circuit. Winter Hi Vis Safety Clothing,Winter Safety Cotton Clothing,Winter Safety Jacket Ningbo Staneex Imp. & Exp. Co., Ltd. , https://www.staneex.com